clinical trial · NCT07107230
A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
Janssen Research & Development, LLC·phase1·recruiting·n = 400
Advanced Stage Solid TumorsJNJ-95437446Amivantamab
brief summary
The purpose of this study is to determine recommended phase 2 doses (RP2Ds) of JNJ-95437446 in Part 1, and to further evaluate the safety of the RP2Ds in participants with advanced solid tumors in Part 2.
started
Jul 15, 2025
primary completion
Nov 18, 2027
completion
Apr 24, 2028
last updated
Nov 3, 2026
official title
A Phase 1 Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol